MedTrace Logo

Autotaxin: a Potential Biomarker for Breast Cancer.

NCT05680311 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2023-01-26

No results posted yet for this study

Summary

The goal of this clinical trial is to test the efficiency of Autotaxin (ATX) as a biomarker for breast cancer patients.

The main questions it aims to answer are;

* is ATX a reliable tumor marker for breast cancer patients in diagnosis
* can ATX differentiate cancer patients from non-cancer ones

Conditions

Interventions

BIOLOGICAL

measurement of serum autotaxin serum level

autotaxin expression

Sponsors & Collaborators

  • Diskapi Yildirim Beyazit Education and Research Hospital

    collaborator OTHER_GOV

  • Ankara Etlik City Hospital

    lead OTHER_GOV

Principal Investigators

  • Duray Seker, Professor · Ankara Etlik City Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2020-12-31
Completion
2021-03-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05680311 on ClinicalTrials.gov